These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 11980652

  • 41. [Effect of recombinant adenovirus Ad-DT-A in targeted therapy for malignant cancer cell lines with loss of IGF2 imprinting].
    Pan YQ, He BS, Zhu C, Qu LL, Xu XF, Wang SK.
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):816-21. PubMed ID: 22335945
    [Abstract] [Full Text] [Related]

  • 42. Transcription-targeted gene therapy for androgen-independent prostate cancer.
    Martiniello-Wilks R, Tsatralis T, Russell P, Brookes DE, Zandvliet D, Lockett LJ, Both GW, Molloy PL, Russell PJ.
    Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
    [Abstract] [Full Text] [Related]

  • 43. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
    Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C.
    Clin Cancer Res; 2008 Jan 01; 14(1):291-9. PubMed ID: 18172281
    [Abstract] [Full Text] [Related]

  • 44. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
    Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P, Yu DC.
    Cancer Gene Ther; 2005 Aug 01; 12(8):715-22. PubMed ID: 15832172
    [Abstract] [Full Text] [Related]

  • 45. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
    Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 2000 Nov 15; 60(22):6526-30. PubMed ID: 11103823
    [Abstract] [Full Text] [Related]

  • 46. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
    Hsieh CL, Yang L, Miao L, Yeung F, Kao C, Yang H, Zhau HE, Chung LW.
    Cancer Res; 2002 Jun 01; 62(11):3084-92. PubMed ID: 12036918
    [Abstract] [Full Text] [Related]

  • 47. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
    Zhang L, Brereton HM, Hahn M, Froscio M, Tilley WD, Brown MP, Barritt GJ.
    Cancer Gene Ther; 2003 Aug 01; 10(8):611-25. PubMed ID: 12872143
    [Abstract] [Full Text] [Related]

  • 48. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.
    Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC.
    Clin Cancer Res; 2001 Dec 01; 7(12):4272-9. PubMed ID: 11751529
    [Abstract] [Full Text] [Related]

  • 49. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
    Tsui KH, Feng TH, Chung LC, Chao CH, Chang PL, Juang HH.
    Anticancer Res; 2008 Dec 01; 28(4A):1969-76. PubMed ID: 18649734
    [Abstract] [Full Text] [Related]

  • 50. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
    Chapel-Fernandes S, Jordier F, Lauro F, Maitland N, Chiaroni J, de Micco P, Mannoni P, Bagnis C.
    Cancer Gene Ther; 2006 Oct 01; 13(10):919-29. PubMed ID: 16741521
    [Abstract] [Full Text] [Related]

  • 51. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
    Bigler D, Gulding KM, Dann R, Sheabar FZ, Conaway MR, Theodorescu D.
    Oncogene; 2003 Feb 27; 22(8):1261-72. PubMed ID: 12606954
    [Abstract] [Full Text] [Related]

  • 52. Cell-specific expression of the diphtheria toxin A-chain coding sequence induces cancer cell suicide.
    Rui H, Chen Y.
    Chin Med J (Engl); 2002 Jun 27; 115(6):869-73. PubMed ID: 12123555
    [Abstract] [Full Text] [Related]

  • 53. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
    Zhao P, Zhu YH, Wu JX, Liu RY, Zhu XY, Xiao X, Li HL, Huang BJ, Xie FJ, Chen JM, Ke ML, Huang W.
    Life Sci; 2007 Aug 09; 81(9):695-701. PubMed ID: 17714738
    [Abstract] [Full Text] [Related]

  • 54. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 09; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 55. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
    Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM.
    Cancer Res; 2001 Mar 15; 61(6):2562-71. PubMed ID: 11289132
    [Abstract] [Full Text] [Related]

  • 56. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T, Onishi T, Franco OE, Arima K, Nishikawa K, Yanagawa M, Hioki T, Watanabe M, Hirokawa Y, Shiraishi T, Sugimura Y.
    Anticancer Res; 2006 Mar 15; 26(5A):3365-71. PubMed ID: 17094454
    [Abstract] [Full Text] [Related]

  • 57. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
    Li Y, Kacka M, Thompson M, Hsieh JT, Koeneman KS.
    Urol Oncol; 2011 Mar 15; 29(6):624-33. PubMed ID: 19963408
    [Abstract] [Full Text] [Related]

  • 58. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 59. [Clinical application for gene therapy in prostate cancer].
    Gotoh A, Kamidono S, Chung LW.
    Hinyokika Kiyo; 1997 Nov 20; 43(11):829-33. PubMed ID: 9436031
    [Abstract] [Full Text] [Related]

  • 60. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.